AP2015008511A0 - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
AP2015008511A0
AP2015008511A0 AP2015008511A AP2015008511A AP2015008511A0 AP 2015008511 A0 AP2015008511 A0 AP 2015008511A0 AP 2015008511 A AP2015008511 A AP 2015008511A AP 2015008511 A AP2015008511 A AP 2015008511A AP 2015008511 A0 AP2015008511 A0 AP 2015008511A0
Authority
AP
ARIPO
Prior art keywords
antiviral compounds
antiviral
compounds
Prior art date
Application number
AP2015008511A
Other languages
English (en)
Inventor
Martin Teresa Alejandra Trejo
John O Link
Jeromy L Cottell
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50974893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008511(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2015008511A0 publication Critical patent/AP2015008511A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2015008511A 2012-12-21 2013-12-19 Antiviral compounds AP2015008511A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745452P 2012-12-21 2012-12-21
US13/830,346 US9233974B2 (en) 2012-12-21 2013-03-14 Antiviral compounds
PCT/US2013/076734 WO2014100500A1 (en) 2012-12-21 2013-12-19 Antiviral compounds

Publications (1)

Publication Number Publication Date
AP2015008511A0 true AP2015008511A0 (en) 2015-06-30

Family

ID=50974893

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008511A AP2015008511A0 (en) 2012-12-21 2013-12-19 Antiviral compounds

Country Status (28)

Country Link
US (5) US9233974B2 (es)
EP (3) EP3404030A1 (es)
JP (1) JP6333849B2 (es)
KR (2) KR102164390B1 (es)
CN (2) CN107011350A (es)
AP (1) AP2015008511A0 (es)
AR (1) AR094262A1 (es)
AU (1) AU2013361195B2 (es)
BR (1) BR112015014333A8 (es)
CA (1) CA2893963C (es)
CL (1) CL2015001702A1 (es)
CR (1) CR20150370A (es)
EA (2) EA027828B1 (es)
ES (1) ES2626392T3 (es)
HK (2) HK1214594A1 (es)
IL (1) IL239496A0 (es)
MA (1) MA38261A1 (es)
MD (1) MD20150062A2 (es)
MX (1) MX2015007888A (es)
PE (1) PE20151423A1 (es)
PH (1) PH12015501354A1 (es)
PL (1) PL2935279T3 (es)
PT (1) PT2935279T (es)
SG (1) SG11201504746PA (es)
SI (1) SI2935279T1 (es)
TW (2) TW201835087A (es)
UY (1) UY35241A (es)
WO (1) WO2014100500A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710567A (en) 2010-11-17 2017-01-27 Gilead Sciences Inc Antiviral compounds
CN105837584B (zh) 2011-11-16 2018-07-13 吉利德制药有限责任公司 作为抗病毒化合物的缩合的咪唑基咪唑
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US9398640B2 (en) 2012-12-21 2016-07-19 Halliburton Energy Services, Inc. Digital multi-use thermo-cup
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TN2016000529A1 (en) 2014-06-17 2018-04-04 Pfizer Substituted dihydroisoquinolinone compounds
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
EP3511331A1 (en) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105732765B (zh) * 2016-02-01 2019-07-26 杭州科巢生物科技有限公司 丙肝药物维帕他韦的新合成方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
AU2018335411B2 (en) * 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors
US12497408B2 (en) 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
RS51974B (sr) 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ710567A (en) 2010-11-17 2017-01-27 Gilead Sciences Inc Antiviral compounds
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae

Also Published As

Publication number Publication date
KR20200118903A (ko) 2020-10-16
TW201835087A (zh) 2018-10-01
EA201590868A1 (ru) 2015-11-30
CN107011350A (zh) 2017-08-04
TW201441229A (zh) 2014-11-01
CL2015001702A1 (es) 2015-08-07
EA201790781A3 (ru) 2017-11-30
EP2935279B1 (en) 2017-03-15
PL2935279T3 (pl) 2017-08-31
PE20151423A1 (es) 2015-10-17
US20140178336A1 (en) 2014-06-26
HK1216177A1 (en) 2016-10-21
EP2935279A1 (en) 2015-10-28
EP3404030A1 (en) 2018-11-21
MD20150062A2 (ro) 2015-12-31
US9233974B2 (en) 2016-01-12
US20160083395A1 (en) 2016-03-24
KR20150100728A (ko) 2015-09-02
CA2893963C (en) 2021-09-07
WO2014100500A1 (en) 2014-06-26
TWI613202B (zh) 2018-02-01
EA027828B1 (ru) 2017-09-29
IL239496A0 (en) 2015-08-31
US20160362416A1 (en) 2016-12-15
KR102164390B1 (ko) 2020-10-12
AU2013361195A1 (en) 2015-06-11
CN104918943A (zh) 2015-09-16
BR112015014333A2 (pt) 2017-07-11
MA38261A1 (fr) 2017-06-30
AU2013361195B2 (en) 2018-05-17
SI2935279T1 (sl) 2017-06-30
UY35241A (es) 2014-07-31
US20180244684A1 (en) 2018-08-30
EA201790781A2 (ru) 2017-08-31
EP3239152A1 (en) 2017-11-01
HK1214594A1 (zh) 2016-07-29
JP6333849B2 (ja) 2018-05-30
JP2016503800A (ja) 2016-02-08
HK1245263A1 (en) 2018-08-24
SG11201504746PA (en) 2015-07-30
US20170369502A1 (en) 2017-12-28
MX2015007888A (es) 2015-09-29
CN104918943B (zh) 2017-04-05
PT2935279T (pt) 2017-06-02
CR20150370A (es) 2015-08-14
AR094262A1 (es) 2015-07-22
CA2893963A1 (en) 2014-06-26
PH12015501354A1 (en) 2015-09-07
ES2626392T3 (es) 2017-07-24
BR112015014333A8 (pt) 2019-10-15

Similar Documents

Publication Publication Date Title
IL239496A0 (en) Antiviral compounds
IL252345A0 (en) Antiviral compounds
SG10201703451RA (en) Antiviral compounds
ZA201502532B (en) Rsv antiviral compounds
IL235986B (en) Tetrahydropyrazolopyrimidine compounds
AP2014007810A0 (en) Imidazopyrrolidinone compounds
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
GB201209096D0 (en) Compounds
GB201219820D0 (en) Compounds
EP2699241A4 (en) ANTIVIRAL COMPOUNDS
GB201217310D0 (en) Compounds
ZA201402374B (en) Antiviral compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218774D0 (en) Compounds
GB201218776D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218018D0 (en) Compounds
GB201217312D0 (en) Compounds